tradingkey.logo

Corvus Pharmaceuticals Announces Positive Early-Stage Soquelitinib Data For Atopic Dermatitis

ReutersJan 20, 2026 12:37 PM

- Corvus Pharmaceuticals Inc CRVS.O:

  • CORVUS PHARMACEUTICALS ANNOUNCES POSITIVE DATA FROM COHORT 4 CONFIRMING RESULTS FOR PLACEBO-CONTROLLED PHASE 1 CLINICAL TRIAL OF SOQUELITINIB FOR ATOPIC DERMATITIS

  • CORVUS PHARMACEUTICALS INC - 75% ACHIEVED EASI 75, 25% EASI 90, 33% IGA 0/1

  • CORVUS PHARMACEUTICALS INC - PLANS PHASE 2 TRIAL FOR SOQUELITINIB IN Q1 2026

  • CORVUS PHARMACEUTICALS : COHORT 4 DATA DEMONSTRATED POSITIVE SAFETY AND EFFICACY RESULTS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI